|
|
|
|
|
|
Tools
Business Unit Strategy: The team worked with the Bio-discovery division of a large life sciences company to help set the division's strategy for
the next 3-7 years. In addition to extensive secondary research, the team interviewed academic, CRO and industry
researchers in the US, EU, China, and India across a range of disciplines including mass spec, flow cytometry, genomics,
biomarker discovery, HTS, and HCS. The team identified target acquisition candidates and developed an execution strategy
for building a business that would address major unmet needs from basic research to translational medicine.
Product Strategy: Health Advances worked with a large life sciences tools company to develop a total market potential for
stem cell derived cells for drug discovery and screening applications. A detailed primary research program with top scientists
at leading pharmaceutical and biotech companies was used to determine likely positions of stem cell derived products as well
as cellular requirements for screening campaigns. Health Advances worked closely with the company's stem cell strategic
initiative planning group to incorporate these findings into their overall strategy.
Corporate Strategy: Facilitated a major strategic objective to identify synergistic product opportunities and subsequent
product packaging for the senior management teams of two large life sciences companies in the process of merging. Through
a series of facilitative meetings with both senior management teams, Health Advances identified, analyzed, and presented
the most favorable synergy opportunities for various functional groups within both organizations. Deliverables included a
qualitative interview program with customers, extensive secondary research, participation and facilitation of key team
meetings, market models for select teams, detailed financial models for each synergy opportunity, and presentations prepared
and presented for each meeting throughout the project.
Service Providers
M&A Support: Conducted commercial diligence on a clinical CRO for a group of private investors. The team participated in
several management meetings with the target, conducted in-depth interviews with CRO customers and industry executives and
extensive secondary research to understand the trends in clinical outsourcing and the relative positioning of the target
to act against these trends. The team developed a robust demand forecast model to assess how the outsourced market would
change over time by therapeutic area, phase, molecule and company type. The team combined these analyses to help inform
the client's successful bid during the auction process.
Go-to Market Strategy: A large CRO client historically focused on GLP-level preclinical animal studies was interested in
understanding the opportunity to offer non-GLP discovery services. Health Advances conducted an extensive internal
research program to understand the company's strengths/weaknesses, the current approach to handling such requests,
and general organizational opinion of the opportunity. We also conducted interviews with customers, KOLs, and competitors
to understand the relative demand for discovery services and the types of models that would be relevant and possible
for a CRO to offer. We worked closely with the client to develop a document outlining the key investments to make,
services/model to offer, and potential acquisition targets to build the business.
Business Unit Strategy: Conducted a market assessment and evaluated market strategies within drug discovery and clinical
biomarker services for a large life sciences company with a discovery services business. By targeting director-level
customers and outsourcing decision-makers within pharma and large biotech, we provided the company with specific detail
around the current use and demand for drug discovery and clinical biomarker services, the major unmet needs, and future
trends. With this information, we developed a strategy to address the services space that matched the industry needs and
leveraged the company's strengths.
Researchers/Developers
Business Development Strategy: Health Advances reviewed the basic research portfolio of a medical school and associated
academic medical center to evaluate and identify individual translational research programs that could be leveraged to
increase the level of industry sponsorship for the institutions. The potential of grouping individual faculty's research
programs into multi-faculty platform areas that could provide "bench-to-beside" translational science capabilities was
also evaluated. In addition, recommendations were made about the internally and externally focused tactics the
university/medical center could pursue to enhance industry funding.
Corporate Strategy: Working with a non-for profit, independent academic research institute, Health Advances evaluated a
number of different sustainability models for the organization to facilitate development of an approach that
would facilitate moving research discoveries and inventions through the translation gap to the market to ensure
patients have access to the best care and an approach that would allow sustained funding of future research
programs. Programs for drug candidates, software packages, research tools and reagents, and education programs were evaluated.
|
|
 |
|
|
|
|
